Cardiopharma, Inc.
The CardiaPill® is a patented platform technology and includes three of the most commonly prescribed CVD medications (US$40BN sales p/a):
- Cholesterol lowering agent ("statin")
- Antihypertensive agent ("ACE inhibitor")
- Anti-platelet drug (aspirin)
All in a single, easy to swallow capsule.
The Product is characterized by having:
- A clear medical need,
- Strong patent protection,
- Buy- in by managed care,
- Buy-in by primary care givers and cardiologist alike
- Large multi-billion dollar global market.
- Zoticon licenses CardiaPill, and incorporates Cardiopharma to develop product
- Cardiopharma strengthens IP position as Zoticon negotiates the licensing of key patents from Harvard University.
- Zoticon and Company devise novel regulatory pathway which is approved in a pre IND meeting with the FDA.
- Zoticon brings in Don Sellers as CEO of the Company. Prior to accepting the position at Cardiopharma, Sellers was the successful CEO of the NASDAQ traded biotech company "Sciclone".
- Zoticon raises a total of 25MM in financing, sufficient to bring drug to an NDA filing.
- Company completes manufacturing and will begin trials in Q2 2013.
Due to Zoticon's regulatory expertise, Cardiopharma is able to utilize a novel regulatory pathway to market. Estimated NDA filing: 2014.
